Ups And Downs See Mid-Table Players Shift Position

After the first part of Generics Bulletin’s annual Top 50 ranking showed how the world’s 10 biggest generics and biosimilars firms had changed position in the past year, that trend has continued into the middle of the pack, as the mixed fortunes of companies occupying positions 11 to 30 have seen some rise up the rankings at the same time as others have slipped down the table.

At the top of our second table we find three major Indian players – Cipla, Dr Reddy’s and Intas – with sales growth in their financial years ended 31 March 2021 that enabled them